Tenax presents Phase 3 LEVEL data showing TNX-103 boosts 6-minute walk distance in lower baseline subgroup

Tenax Therapeutics presented additional Phase 3 LEVEL results for TNX-103 in a late-breaking session at ESC Congress 2026.

The trial missed its main efficacy goals in the overall study population, raising uncertainty around the current registrational strategy.

Subgroup results pointed to clearer functional benefit in more impaired patients, supported by improvements in biomarkers and cardiac pressure measures.

Management plans to redesign LEVEL-2 to enrich enrollment toward patients most likely to respond, aiming to preserve a path to approval.